Smart-Money SignalNeutral · 51/100— Insider open-market flow is flat over 90 days
Revenue$330.5M
Net Income$331.0M
EPS$2.88
Gross Margin109.1%
Market Cap$2.1B
Price Performance
Historical data including institutional events
Company Profile
D
Douglas S. Ingram
CEO & Executive Director
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
